Atomoxetine's effect on societal costs in Sweden

Journal of Attention Disorders

Volumn 13, Issue 6, 2010, Pages 618-628

  Myrén, Karl Johan ^a   Thernlund, Gunilla ^b   Nylén, Åsa ^c   Schacht, Alexander ^d   Svanborg, Pär ^e  

^a IQVIA   (United States)

^b LUND UNIVERSITY   (Sweden)

^c Eli Lilly Sweden AB ^*  (Sweden)

^d LILLY DEUTSCHLAND GMBH   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ADHD; Atomoxetine; Health care costs; Societal costs

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; ATOMOXETINE; PROPYLAMINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; MENTAL HEALTH SERVICE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; SWEDEN;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MENTAL HEALTH SERVICES; PREVALENCE; PROPYLAMINES; SWEDEN;

EID: 77951790512     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054709332163     Document Type: Article

References (21)

1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., Text revision). Washington, DC: Author.
2. Barkley, R.A., & Cox, D. (2007). A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. Journal of Safety Research, 38, 113-128.
3. Brown, R.T., Freeman, W.S., Perrin, J.M., Stein, M.T., Amler R.W. Feldman H.M.,et al.(2001). Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics, 107, E43.
4. De Ridder, A., & De Graeve, D. (2006). Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clinical Drug Investigation, 26, 75-90.
5. Gibson, A.P., Bettinger, T.L., Patel, N.C., & Crismon, M.L. (2006). Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Annals of Pharmacotherapy, 40, 1134-1142.
6. Goossens, M.E.J.B., Rutten-van Mölken, M.P.M.H., Vlaeyen, J.W.S., & van der Linden, S.M.J.P. (2000). The cost diary: A method to measure direct and indirect costs in cost-effectiveness research. Journal of Clinical Epidemiology, 53, 688-695.
7. Guevara, J., Lozano, P., Wickizer, T., Mell, L., & Gephart, H. (2001). Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics, 108, 71-78.
8. Jensen, P.S., Garcia, J.A., Glied, S., Crowe, M., Foster, M., Schlander, M.,et al.(2005). Cost-effectiveness of ADHD treatments: Findings from the Multimodal Treatment Study of children with ADHD. American Journal of Psychiatry, 162, 1628-1636.
9. Kaufman, J., Birmaher, B., Brent, D., Rao, U., Flynn, C., Moreci, P.,et al.(1997). Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. Journal of American Academy of Child and Adolescent Psychiatry. 36, 980-989.
10. King, S., Griffin, S., Hodges, Z., Weatherly, H., Asseburg, C., Richardson G.,et al.(2006). A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technology Assessment, 10, No. 23.
11. Matza, L.S., Paramore, C., & Prasad, M. (2005). A review of the economic burden of ADHD. Cost Effectiveness and Resource Allocation, 3, 5.
12. National Institutes of Health Consensus Development Conference Statement (1998). Diagnosis and treatment of attention/deficit/ hyperactivity disorder (ADHD). Journal of the American Academy of Child and Adolescent Psychiatry, 39, 182-188.
13. Nydén, A., Paananen, M., & Gillberg, C. (2000). Betydande underdiagnostik av neuropsykiatriska problem hos barn. Riktade åtgärdsprogram ger bättre och billigare vård. [Neuropsychiatric problems among children are significantly underdiagnosed. Intervention programs result in better and less expensive care]. Läkartidningen, 97, 5634-5639, 5641.
14. Nydén, A., Myren, K.J., & Gillberg, C. (2008). Long-term psychosocial and health economy consequences of ADHD, autism, and reading-writing disorder: A prospective service evaluation project. Journal of Attention Disorders, 12; 141.
15. Pelham, W.E., Foster, E.M., & Robb, J.A. (2007). The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. Ambulatory Pediatrics, 7(Suppl. 1), 121-131.
16. Remschimdt, H., Global ADHD Working Group. (2005). Global consensus on ADHD/HKD. European Child and Adolescent Psychiatry, 14, 127-137.
17. Svanborg, P., Thernlund, G., Gustafsson, P.A., Hägglöf, B., Poole, L., & Kadesjö. B. (in press). Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of Attention-deficit/ Hyperactivity Disorder: A randomized, double-blind placebo controlled study in stimulant-naïve Swedish children and adolescents. European Child and Adolescent Psychiatry.
18. Svanborg, P., Thernlund, G., Gustafsson, P.A., Hägglöf, B., Schacht. A., & Kadesjö. B. (2009). Atomoxetine improves patient and family coping in Attention Deficit/ Hyperactivity Disorder: A randomized, double-blind placebo controlled study in stimulant-naïve Swedish children and adolescents. Manuscript submitted for publication.
19. Swedish County Council. (2005). http://www.vgregion.se/upload/svn%20-%20samverkansn%c3%a4mden/PDF-fil%20utoml%c3%a4nsprislista%202007.pdf?epslanguage=sv.
20. Swensen, A., Birnbaum, H.G., Ben Hamadi, R., Greenberg, P., Cremieux, P.Y., & Secnik, K. (2004). Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients. Journal of Adolescent Health, 35, 346, e1-e9.
21. Swensen, A., Birnbaum, H.G., Secnik, K., Marynchenko, M., Greenberg, P., & Claxton, A. (2003). Attention-deficit/hyperactivity disorder: Increased costs for patients and their families. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 1415-1423.